AI drug discovery vendors are analyzing data (e.g., clinical trials data, EHRs, omics data, cellular images, and more) to develop novel drugs.
Your future customers are researching their next tech solution on CB Insights. Make sure they can find you.
Claim your CB Insights ProfileLeaders are the most established service providers in the market and possess the breadth to address various customer needs.
See why these companies made it as leaders for AI Drug Discovery Platforms. These companies include Atomwise.
United States / Founded Year: 2012
Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.
FutuRx, University of Connecticut, University of Kentucky, and 2 more
Abraham Heifets, Jonathan Barr, Izhar Wallach
Highfliers are the most innovative service providers in the market and possess the resources to address evolving customer needs.
See why these companies made it as highfliers for AI Drug Discovery Platforms. These companies include XtalPi and insitro.
China / Founded Year: 2014
XtalPi is a cloud-based technology company that solves drug polymorphism by providing accurate computational crystal structure prediction for small-molecule drugs.
Signet Therapeutics, Genhouse, ReviR Therapeutics, and 2 more
Jian Ma, Shuhao Wen, Ronald Tam, and 2 more
United States / Founded Year: 2018
insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.
Daphne Koller, Keith James, Saeid Akhtari, and 1 more
Outperformers are the most specialized service providers in the market and possess the expertise to address unique customer needs.
See why these companies made it as outperformers for AI Drug Discovery Platforms. These companies include Healx and Cyclica.
United Kingdom / Founded Year: 2014
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.
Ovid Therapeutics, Polycystic Kidney Disease Charity, Mission: Cure, and 1 more
David Brown
Canada / Founded Year: 2013
Cyclica is a global biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica's structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.
Structural Genomics Consortium, Impact Therapeutics, FMC Corporation
Naheed Kurji
Canada / Founded Year: 2014
Deep Genomics develops individualized genetic medicines by creating AI systems that are used to accelerate all steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment, and trial design.
Montreal Institute for Learning Algorithms, BioMarin Pharmaceutical, WAVE Life Sciences
Brendan Frey, Ferdinand E Massari
Challengers are the most promising service providers in the market and possess the agility to address emerging customer needs.
See why these companies made it as challengers for AI Drug Discovery Platforms. These companies include .
AI drug discovery vendors are analyzing data (e.g., clinical trials data, EHRs, omics data, cellular images, and more) to develop novel drugs.
Your future customers are researching their next tech solution on CB Insights. Make sure they can find you.
Claim your CB Insights Profile